HETRAZAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hetrazan, and what generic alternatives are available?
Hetrazan is a drug marketed by Lederle and is included in one NDA.
The generic ingredient in HETRAZAN is diethylcarbamazine citrate. There are five drug master file entries for this compound. Additional details are available on the diethylcarbamazine citrate profile page.
Summary for HETRAZAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 87 |
Clinical Trials: | 1 |
Patent Applications: | 394 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HETRAZAN at DailyMed |
Recent Clinical Trials for HETRAZAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Washington University School of Medicine | Phase 3 |
Regional Hospital of Agboville, Southern Cote d'Ivoire | Phase 3 |
Case Western Reserve University | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for HETRAZAN
US Patents and Regulatory Information for HETRAZAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lederle | HETRAZAN | diethylcarbamazine citrate | TABLET;ORAL | 006459-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |